Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CFO Sells 1,767 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Brian Piekos sold 1,767 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the sale, the chief financial officer directly owned 13,762 shares of the company’s stock, valued at $214,274.34. The trade was a 11.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock traded up $0.21 during mid-day trading on Tuesday, reaching $15.77. 751,567 shares of the stock traded hands, compared to its average volume of 635,299. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.23 and a 12-month high of $19.00. The business’s 50-day moving average is $15.47 and its 200-day moving average is $13.94. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The stock has a market capitalization of $797.17 million, a PE ratio of -3.99 and a beta of -0.19.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of KALV. The Manufacturers Life Insurance Company boosted its stake in shares of KalVista Pharmaceuticals by 5.9% in the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock worth $165,000 after acquiring an additional 818 shares during the period. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Rhumbline Advisers lifted its holdings in KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after purchasing an additional 1,458 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in KalVista Pharmaceuticals by 26.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock worth $110,000 after purchasing an additional 2,061 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in KalVista Pharmaceuticals by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 324,369 shares of the specialty pharmaceutical company’s stock worth $5,239,000 after purchasing an additional 2,402 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on KALV shares. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. HC Wainwright lifted their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Needham & Company LLC boosted their price objective on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Finally, Citizens Jmp lowered their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Tuesday, November 11th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.